AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04562597
Drug: Dose Response Curve N-acetylcysteine 150 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
Trial: NCT04562597
Drug: Opioid Reduction with Optimal N-acetylcysteine Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once the optimal N-acetylcysteinedose is identified, 15 participants will be randomized to the optimal dose (50,100, or 150 mg/kg) to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
Trial: NCT04562597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
Trial: NCT05908409
Drug: IDP-121
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-121 is a new chemical entity specifically designed to directly target cMyc protein that has demonstrated activity in multiple liquid and solid tumor cell lines and preclinical animal models
Trial: NCT06069141
Drug: Benzathine Penicillin G
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzathine Penicillin G (2.4 MU intramuscularly once)
Trial: NCT06069141
Drug: Doxycycline Capsule
RxNorm normalized name: Doxycycline Capsules
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxycycline (100 mg orally twice daily for 7 days)
Trial: NCT04883528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
Trial: NCT00041171
Drug: Hypericum perforatum
RxNorm normalized name: Hypericum perforatum
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05286372
Drug: AMX0035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary formulation of sodium phenylbutyrate and taurursodiol
Trial: NCT05764668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 daily- doses of placebo，one bag at a time (15 g/bag), three times/day
Trial: NCT05424263
Drug: Calcium Acetate Oral Solution
RxNorm normalized name: Calcium Acetate Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be supplemented with calcium acetate (4,000 mg/day), as described in the arm/group descriptions, for 12 weeks.
Trial: NCT05786365
Drug: Ketalar 50 MG/ML Injectable Solution
RxNorm normalized name: Ketalar 50 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg
Trial: NCT04104919
Drug: Placebo 6 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative intrathecal injection
Trial: NCT05203367
Drug: BAR502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 240 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 10, 50 and 150 mg. A maximum of 4 dose levels are pre-planned (10 mg, 50 mg, 150 mg, 300 mg).
Trial: NCT05203367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
Trial: NCT01004016
Drug: KPS-0373
RxNorm normalized name: Draxxin KP
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01004016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05027932
Drug: BPL-1357
RxNorm normalized name: BANDAGE KIT,COMPRESSION LYMPHEDEMA#BPLEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPL-1357 contains 4 whole inactivated avian influenza viruses: A /Environment /Maryland/261/2006 H7N3, A/Mallard /Maryland/802/2007 H5N1, A/Pintail/Ohio /339/1987 H3N8, and A/Mallard/Ohio /265/1987 H1N9. It will be administered either IM or IN depending on the assigned treatment group.
Trial: NCT05938920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical formulation: Capsules~Mode of Administration: Oral
Trial: NCT04959812
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive Sufentanil while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
Trial: NCT06120595
Drug: REBECCA-assisted intervention 1
RxNorm normalized name: DRESSING,QUIKCLOT INTERVENTION 1.5X1.5IN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention will include changes in medication (e.g. change from Letrozol to Tamoxifen, treatment for polyneuropathy, osteoporosis).
Trial: NCT05330858
Drug: ESK-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet or liquid
Trial: NCT05593614
Drug: ATX01 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 100 mL bottle of hydrogel formulation containing 10% amitriptyline hydrochloride w/w
Trial: NCT05593614
Drug: ATX01 15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 100 mL bottle of hydrogel formulation containing 15% amitriptyline hydrochloride w/w
Trial: NCT05593614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 100 mL bottle of hydrogel formulation containing no active substance
Trial: NCT06196398
Drug: Standard Medical Treatment on the basis of anti-platelet therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Anti-platelet therapy: aspirin 75mg+clopidogrel 100mg will be applied for patients with severe ICAS stenosis (70%-90%) suffering stroke or TIA within 30 days. After 90 days, single anti-platelet therapy will be continued.~2. Intensive statin therapy: Statins with high doses~3. Blood pressure: below 140/90mmHg~4. LDL: less than 1.81mmol/L(70mg/dl)~5. Fasting blood glucose controlled to 5.9mmol/L, and glycosylated hemoglobin A1c reduced to less than 7%~6. Cigarette and alcohol quitting~7. Oral anticoagulants for atrial fibrillation
Trial: NCT05857449
Drug: LPM3480392
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT05828472
Drug: MY008211A tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MY008211A tablets, low/moderate/high dose orally, for 7 days
Trial: NCT05828472
Drug: MY008211A tablets matched placebo
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days
Trial: NCT05343234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tree different placebo drugs with tree different names and scheduled will be given
Trial: NCT05512702
Drug: Low-molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the anticoagulation treatment group receive this treatment and do not receive thrombolytic treatment.
Trial: NCT05162001
Drug: Disulfiram 250 mg
RxNorm normalized name: disulfiram 250 MG
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram used qd during nine weeks to observe effects on body weight
Trial: NCT02677636
Drug: MSRD-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSRD-100 is a topical gel.
Trial: NCT02677636
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle is a topical gel without the active ingredients in MSRD-100
Trial: NCT05136898
Drug: UGN-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
Trial: NCT04993729
Drug: T89 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T89 capsule (trade name Dantonic®) is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~T89 capsules, p.o. TID.
Trial: NCT04993729
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, p.o. TID.
Trial: NCT05341999
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will be prescribed ibuprofen medication as a single dose immediately after completion of root canal treatment.
Trial: NCT00633230
Drug: standardized herbal formula, Sho-saiko-to (SST)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules containing 700 mg of the Sho-saiko-to (SST) herbal extract/capsule and 28 mg of the excipients, magnesium stearate, and silicon dioxide/capsule 2 x day
Trial: NCT05411861
Drug: Analgesic Non Narcotic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of protocol-specified volume of local analgesic
Trial: NCT04104659
Drug: MK 6240
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET tracer, \[18F\]MK-6240 (an\[18F\]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.(Hostetler, Walji et al. 2016, Lohith, Bennacef et al. 2016, Walji, Hostetler et al. 2016, Lohith, Bennacef et al. 2017, Neelamegam, Yokell et al. 2017).We will evaluate this imaging agent in individuals from families with a known Autosomal Dominant Alzheimer's Disease (ADAD) mutation.~The planned dosage for \[18F\]MK-6240 is a single intravenous bolus injection of 185 MBq (5.0 mCi) in a large peripheral vein followed by a 10 mL normal saline (0.9% NaCl) flush.
Trial: NCT06351215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill that is identical look-alike to study drug
Trial: NCT02223416
Drug: RGB-10
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05868733
Drug: Day 1 Higher Dose (1×107 pfu)
RxNorm normalized name: herpesvirus 1, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rVSV∆G-LASV-GPC
Trial: NCT05868733
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05124457
Drug: Insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are to receive insulin NPH
Trial: NCT05039658
Drug: IBI110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI110 is a high-affinity, ligand-blocking, humanized anti- Lymphocyte Activation Gene-3 (LAG-3) IgG4 antibody that blocks the binding of LAG-3 to MHCII.
Trial: NCT05476432
Drug: FOLFOX 2d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 46 hours
Trial: NCT04656106
Drug: Ryzodeg®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in South Korea. Hence independently of this study, the treating physician has determined the starting dose of Ryzodeg® as well as any dose adjustments thereafter.
Trial: NCT04186247
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weeks 4-12: 7.5 mg/kg azithromycin once daily (500 mg/day maximum) for five consecutive days/ week for 4 weeks, and 3 times a week for the following 4 weeks
Trial: NCT06282965
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile solution of 0.9% NaCl in water.
Trial: NCT04791059
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
Trial: NCT05823844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo pill will look identical to Suvorexant and will be taken as 2 tablets.
Trial: NCT05007977
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single SC injection of placebo during hypoglycemic clamp
Trial: NCT05720364
Drug: TP-05 (lotilaner oral), fasted group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP-05 (lotilaner oral), fasted group
Trial: NCT05720364
Drug: TP-05 (lotilaner oral), high-fat group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP-05 (lotilaner oral), high-fat group
Trial: NCT05720364
Drug: TP-05 (lotilaner oral), low-fat group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP-05 (lotilaner oral), low-fat group
Trial: NCT04626089
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to placebo will take a tablet bid (PO) plus standard treatment for 14 days
Trial: NCT05300841
Drug: estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Shering, Germany)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will receive dydrogestrone 10mg /day plus estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Schering, Germany) for 10 days.
Trial: NCT06250062
Drug: Recombinant humanized IL-17A Monoclonal Antibody（JS005）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT06250062
Drug: Placebo（JS005）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT04095689
Drug: IL-12 gene therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenoviral-mediated IL-12
Trial: NCT01309022
Drug: Mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
Trial: NCT06508372
Drug: topical placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each patient a single similar psoriatic plaque on the other side of the body \[as regard anatomical site, size and TES (thickness, erythema, scales) score\] will be treated with placebo ointment twice daily for 3 months as a control.
Trial: NCT04866355
Drug: Hyoscine and Ibuprofen
RxNorm normalized name: hydrocodone and ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyoscine (20 mg) and ibuprofen (400 mg) administered by oral via.
Trial: NCT06429579
Drug: Only conventional drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)
Trial: NCT04809974
Drug: Niagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention consists of taking Niagen and completing all tasks divided into 6 visits.
Trial: NCT03191370
Drug: Local Anesthetics,Topical
RxNorm normalized name: LOCAL ANESTHETICS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthetic spray
Trial: NCT05759468
Drug: Investigational Product - MIB 626
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, \>75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.
Trial: NCT05759468
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
Trial: NCT05669586
Drug: Antitumor therapy guided by organoid drug sensitivity test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antitumor therapy guided by organoid will be given to Multi-line Drug-resistant Non-small Cell Lung Cancer patients.
Trial: NCT05202821
Drug: PRG Barrier Coat
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 arm randomized single blind clinical trial comparing 3 groups. first group will be receiving fluoride varnish, second group will be receiving PRG Barrier Coat and the third group will be receiving MI paste
Trial: NCT05202821
Drug: MI paste
RxNorm normalized name: MI Paste One Fresh Mint Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third group will be receiving MI paste
Trial: NCT05045170
Drug: Influence of spinal anesthesia on memory consolidation and 'working memory'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to operation (stage 1), 5-10 minutes after the start of operation (stage 2), 10 minutes before the end of operation (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
Trial: NCT06135363
Drug: SC1011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC1011 tablet
Trial: NCT06135363
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC1011-matching placebo tablet
Trial: NCT04576078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h. Oral placebo is prepared ex-tempore with a taste masking compound by a non-charge nurse following detailed instructions
Trial: NCT04988997
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBO - weekly SC administration
Trial: NCT06358586
Drug: Tachipirina® 120 mg/5 mL oral suspension, new flavour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of the Tachipirina® 120 mg/5 mL oral suspension(10 mL) will be administered to healthy paediatric volunteers under fasting conditions for at least 1 h before IMP administration until completion of palatability assessment.
Trial: NCT04216927
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gNO will be entrained at 20 ppm into the oxygenator of the CPB circuit
Trial: NCT05801055
Drug: Evaluation of gastric visibility following the combination drink of N-acetyle cysteine and simethocone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The combination drink containing N-acetyl cysteine and simethicone help to disperse bubbles and mucus present in the stomach. During routine upper gastrointestinal endoscopy mucus and bubbles sometimes may hinder mucosal visibility, so small submucosal lesions, ulcers, erosions, and even flat pre-malignant lesions can be missed during endoscopy. The Japanese guidelines also recommend the use of this combination drink to detect early gastric cancers. So we plan to evaluate the role of this drink in improving gastric mucosal visibility in patients undergoing upper gastrointestinal endoscopy.
Trial: NCT05737277
Drug: Gabapral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period.
Trial: NCT05737277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period
Trial: NCT05429073
Drug: RGLS8429
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for subcutaneous injection
Trial: NCT05429073
Drug: Placebo volume-matching RGLS8429 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for subcutaneous injection
Trial: NCT06397508
Drug: AGMB-129
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will receive 3 study interventions, 1 in each intervention period
Trial: NCT03859921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with appearance similar to Dydrogesterone
Trial: NCT05644093
Drug: SPL026 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dosing
Trial: NCT05644093
Drug: SPL026 IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM dosing